The effect of Atorvastatin therapy tumour necrosis factor- and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

S.S. Soedamah-Muthu, V. Charlton-Menys, W. Bao, C.G. Schalkwijk, C.D.A. Stehouwer, H.M. Colhoun, D.J. Betteridge, P. Durrington, G. Hitman, H.A.W. Neil, S.J. Livingstone, J.H. Fuller, D.A. DeMicco, G.M. Preston

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82–2.86), sVCAM-1 865 ng/mL (729–1059) and sICAM-1 619 ng/mL (533–753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66–1.0) and 0.59 (95% CI 0.50–0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD
Original languageEnglish
Pages (from-to)288-297
JournalThe British journal of diabetes and vascular disease
Volume11
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Vascular Cell Adhesion Molecule-1
Cell Adhesion Molecules
Intercellular Adhesion Molecule-1
Type 2 Diabetes Mellitus
Coronary Disease
Blood Vessels
Tumor Necrosis Factor-alpha
Cardiovascular Diseases
Therapeutics
Placebos
Confidence Intervals
Placebo Effect
Atorvastatin Calcium

Cite this

Soedamah-Muthu, S.S. ; Charlton-Menys, V. ; Bao, W. ; Schalkwijk, C.G. ; Stehouwer, C.D.A. ; Colhoun, H.M. ; Betteridge, D.J. ; Durrington, P. ; Hitman, G. ; Neil, H.A.W. ; Livingstone, S.J. ; Fuller, J.H. ; DeMicco, D.A. ; Preston, G.M. / The effect of Atorvastatin therapy tumour necrosis factor- and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. In: The British journal of diabetes and vascular disease. 2011 ; Vol. 11, No. 6. pp. 288-297.
@article{136a8bc1eed84c2598ffaa19c97f2900,
title = "The effect of Atorvastatin therapy tumour necrosis factor- and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease",
abstract = "We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70{\%} were men. TNFa 2.20 pg/mL (1.82–2.86), sVCAM-1 865 ng/mL (729–1059) and sICAM-1 619 ng/mL (533–753) concentrations (median, interquartile range 25, 75{\%}) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95{\%} confidence interval (CI) 0.66–1.0) and 0.59 (95{\%} CI 0.50–0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD",
author = "S.S. Soedamah-Muthu and V. Charlton-Menys and W. Bao and C.G. Schalkwijk and C.D.A. Stehouwer and H.M. Colhoun and D.J. Betteridge and P. Durrington and G. Hitman and H.A.W. Neil and S.J. Livingstone and J.H. Fuller and D.A. DeMicco and G.M. Preston",
year = "2011",
doi = "10.1177/1474651411425112",
language = "English",
volume = "11",
pages = "288--297",
journal = "The British journal of diabetes and vascular disease",
issn = "1474-6514",
publisher = "SAGE Publications",
number = "6",

}

Soedamah-Muthu, SS, Charlton-Menys, V, Bao, W, Schalkwijk, CG, Stehouwer, CDA, Colhoun, HM, Betteridge, DJ, Durrington, P, Hitman, G, Neil, HAW, Livingstone, SJ, Fuller, JH, DeMicco, DA & Preston, GM 2011, 'The effect of Atorvastatin therapy tumour necrosis factor- and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease', The British journal of diabetes and vascular disease, vol. 11, no. 6, pp. 288-297. https://doi.org/10.1177/1474651411425112

The effect of Atorvastatin therapy tumour necrosis factor- and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. / Soedamah-Muthu, S.S.; Charlton-Menys, V.; Bao, W.; Schalkwijk, C.G.; Stehouwer, C.D.A.; Colhoun, H.M.; Betteridge, D.J.; Durrington, P.; Hitman, G.; Neil, H.A.W.; Livingstone, S.J.; Fuller, J.H.; DeMicco, D.A.; Preston, G.M.

In: The British journal of diabetes and vascular disease, Vol. 11, No. 6, 2011, p. 288-297.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The effect of Atorvastatin therapy tumour necrosis factor- and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

AU - Soedamah-Muthu, S.S.

AU - Charlton-Menys, V.

AU - Bao, W.

AU - Schalkwijk, C.G.

AU - Stehouwer, C.D.A.

AU - Colhoun, H.M.

AU - Betteridge, D.J.

AU - Durrington, P.

AU - Hitman, G.

AU - Neil, H.A.W.

AU - Livingstone, S.J.

AU - Fuller, J.H.

AU - DeMicco, D.A.

AU - Preston, G.M.

PY - 2011

Y1 - 2011

N2 - We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82–2.86), sVCAM-1 865 ng/mL (729–1059) and sICAM-1 619 ng/mL (533–753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66–1.0) and 0.59 (95% CI 0.50–0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD

AB - We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82–2.86), sVCAM-1 865 ng/mL (729–1059) and sICAM-1 619 ng/mL (533–753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66–1.0) and 0.59 (95% CI 0.50–0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD

U2 - 10.1177/1474651411425112

DO - 10.1177/1474651411425112

M3 - Article

VL - 11

SP - 288

EP - 297

JO - The British journal of diabetes and vascular disease

JF - The British journal of diabetes and vascular disease

SN - 1474-6514

IS - 6

ER -